Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC

ASCO GU 2025

13 - 15 Feb 2025

Published: 20 Feb 2025

Views: 8

Rating:

Save

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

Dr Omid Yazdanpanah speaks to ecancer about the efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC.

This VISION secondary analysis assesses Lutetium PSMA for metastatic castration-resistant prostate cancer, showing improved progression-free and overall survival compared to standard care.

The analysis highlights patient characteristics and notes a significant survival benefit for those receiving concurrent ARPIs.

While safety profiles are similar, the study's retrospective nature presents limitations. Future randomised trials aim to further explore the efficacy and safety of this treatment approach.

Related Videos

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide...

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer